Navigation Links
Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System

Key words: H1 receptor • GPCR • receptor binding assay • LEADseeker • SPA Imaging Beads


Histamine is a biogenic amine that plays important pathophysiological roles in central and peripheral tissues. Generally released from stimulated mast cells, it contributes to several biological processes that characterize allergic responses (1).The function of histamine is mediated via four G protein-coupled receptors, H1, H2, H3 and H4 (2). H1 receptor antagonists are one of the most commonly used class of drugs used to relieve the symptoms of allergic diseases, such as allergic rhinitis, atopic dermatitis, psoriasis and allergic conjunctivitis (3). The H1 receptor is thought to be involved in mediating inflammatory responses via effects on cytokine production (4).

This application note describes a 384-well histamine H1 receptor binding assay developed using the LEADseeker™ Multimodality Imaging System.


Materials
Products used

LEADseeker Multimodality Imaging System 18-1140-71

Wheat Germ Agglutinin (WGA) YOx SPA RPNQ0270
Imaging Beads

[pyridinyl-5-3H]Pyrilamine TRK608


Other materials required
Human recombinant Histamine (Euroscreen, ES-390-M)
H1 receptor membrane preparation

Pyrilamine maleate salt (Sigma, P5514)

Triprolidine hydrochloride (Sigma, T6764)

Costar™ solid white 384-well (Corning, 3705)
non-treated assay plate

Protease-free BSA (Sigma, A3059)

Buffer:
50-mM Tris pH 7.4
5-mM MgCl2
0.2% BSA (w/v)

Graphpad Prism™ software v4.0 (GraphPad Software)


Protocol
Human recombinant Histamine H1 receptor membrane preparation was used in conjunction with [pyridinyl-5-3H]Pyrilamine ligand and WGA YOx SPA Imaging Beads. Non-specific binding (NSB) was determined in the presence of 10-µM pyrilamine. The standard assay format was as follows:

1. Reagents were added in the following order: buffer, unlabeled ligand (NSB wells), labeled ligand, premixed bead and membrane. Total assay volume was 50 µl.

2. Diluted bead and membrane was premixed immediately prior to addition to the wells.

3. Wells contained 10 µl of 28-nM [pyridinyl-53H]Pyrilamine (final concentration 5.6 nM) unless otherwise stated. Wells also contained 5 µg of membrane and 500 µg of WGA YOx SPA Imaging Beads. Bead and membrane were premixed immediately prior to addition to the wells. Premixed bead and membrane was added in a 20-µl volume.

4. NSB wells contained 10 µl of 50-µM pyrilamine (final concentration 10 µM) in addition to the above.

5. Plates were sealed and incubated in darkness for 3 h at room temperature (20–25 ºC) unless otherwise stated.

6. Following incubation, plates were imaged on the LEADseeker Multimodality Imaging System for 5 min using q uasi-coincident averaging and 3 × 3 binning.


Results
Kd determination

Saturation binding was performed with dilutions of [pyridinyl-5-3H]Pyrilamine to give a range of concentrations from 0.13 to 33.2 nM in the wells. Plates were incubated for 5 h at room temperature and in darkness prior to imaging. Figure 1 shows the saturation curve, which was fitted using non-linear regression with the data analysis software package GraphPad Prism v4.0. Over two experiments the mean Kd value was determined to be 3.7 nM (95% confidence intervals 3.1–4.4 nM), estimated directly from the curve. Figure 1 is representative of the data obtained.


DMSO tolerance
Dilutions of DMSO were prepared in assay buffer to give a range of concentrations from 0.25% (v/v) to 5% (v/v) in the wells. The results shown in Figure 2 indicate the assay was tolerant to a final concentration of 2% (v/v). However, the signal was only slightly reduced in the presence of 5% DMSO.

IC50 determination
Competitive binding of 5.6-nM [pyridinyl-5-3H]Pyrilamine with pyrilamine (Fig 3A) and triprolidine (Fig 3B) was assessed and the IC50 of each ligand calculated. Final concentrations in the well ranged from 0.005 to 10 000 nM respectively. DMSO was present at a final concentration of 2% (v/v) in each well.

Over two experiments, the mean pyrilamine IC50 value was determined to be 14.6 nM (95% confidence interval range 10.6–20.7 nM) and the mean Ki value was 5.7 nM (95% confidence intervals 4.2–7.9 nM). The mean triprolidine IC50 value was determined to be 6.9 nM (95% confidence interval range 5.3–9.4 nM) and the mean Ki value was 2.7 nM (95% confidence intervals 2.1–3.6 nM). Figures 3A and 3B are representative of the data obtained.

Time course
A time course was performed using standard reagent concentrations detailed in the protocol with an increased incubation time of 18 h. The assay appeared to be stable for at least 18 h as demonstrated by the curve in Figure 4.

Z’ analysis
Finally, two independent Z’ analysis (5) evaluations were performed, each using 48 replicate values for "total" and NSB wells. DMSO was present at a final concentration of 2% (v/v) in each well. A mean Z’ value of 0.82 was generated. Figure 5 is representative of the data obtained. This is well within the acceptable Z’ value range (0.5–1.0) and confirmed the robustness of the assay.


Conclusion
The histamine H1 receptor binding assay has been successfully miniaturized to a 384-well format using the LEADseeker Multimodality Imaging System and is suitable for adaptation to automated screening formats. The assay is tolerant to DMSO up to a concentration of 2% (v/v), robust; achieving a Z’ value of 0.82 and a stability window of at least 18 h.


References
1. Hill, S. J. et al. Pharmacological Reviews 49, 253–278 (1997).
2. Oda, T. et al. Journal Biological Chemistry 275, 36781-36786 (2000).
3. Curran, M. P. et al. Drugs 64, 523-561 (2004).
4. Matsubara, M. et al. Biochemical Pharmacology 69, 433-449 (2004).
5.Zhang, J. et al. Journal Biomolecular Screening 4 (2), 67–73 (1999).



back to top
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
2. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
3. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
4. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
5. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
6. Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
7. Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System
8. Development of a CRF1 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
9. Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets.
10. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
11. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/30/2016)... , Nov. 30, 2016 /PRNewswire/ - Portage Biotech ... Securities Exchange: PBT.U), is excited to announce the ... focused on developing preclinical ophthalmology assets through proof ... potent anti-inflammatory created by Portage Pharmaceuticals Limited and ... with ocular surface and anterior segment diseases. This ...
(Date:11/30/2016)... -- The Allen Institute for Cell Science has released ... collection of gene edited, fluorescently tagged human induced ... with unprecedented clarity. Distributed through the Coriell Institute ... crucial first step toward visualizing the dynamic organization ... cells healthy and what goes wrong in disease. ...
(Date:11/30/2016)... 2016  Tempus, a technology company focused on ... Abramson Cancer Center have partnered to better determine ... immunotherapy treatment based on next generation genomic and ... a research collaboration, Tempus will provide sequencing and ... data to Penn. Utilizing next-generation sequencing, machine learning ...
(Date:11/30/2016)... , 30. November 2016   Merck ... heute die Unterzeichnung einer Reihe von Vereinbarungen ... wird Evotec AG Screeningleistungen für Mercks Palette ... Der Zugriff auf diese Bibliotheken in Kombination ... einen schnelleren Weg zur Ermittlung und Erforschung ...
Breaking Biology Technology:
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, a ... for public safety, investigation, corrections and monitoring, announced today ... competitor, ICSolutions, to have an independent technology judge determine ... most modern high tech/sophisticated telephone calling platform, and the ... that they do most of what we do – ...
(Date:11/15/2016)... DUBLIN , Nov 15, 2016 Research ... - Global Forecast to 2021" report to their offering. ... ... reach USD 16.18 Billion by 2021 from USD 6.21 Billion in ... Growth of the bioinformatics market is driven by ...
Breaking Biology News(10 mins):